Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma

Allison Rosenthal; Javier Munoz; Monika Jun; Tongsheng Wang; Alex Mutebi; Anthony Wang; Shibing Yang; Kojo Osei-Bonsu; Brian Elliott; Fernando Rivas Navarro; Junhua Yu; Samantha Brodkin; Mariana Sacchi; Andrew Ip

doi:10.1186/s13045-024-01594-x

Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma

Allison Rosenthal, Javier Munoz, Monika Jun, Tongsheng Wang, Alex Mutebi, Anthony Wang, Shibing Yang, Kojo Osei-Bonsu, Brian Elliott, Fernando Rivas Navarro, Junhua Yu, Samantha Brodkin, Mariana Sacchi, Andrew Ip

School of Medicine

Hackensack Meridian School of Medicine

Research output: Contribution to journal › Letter › peer-review

Abstract

Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of therapy, albeit with scant evidence on the comparative effectiveness of these therapies. This study used inverse probability of treatment weighting to indirectly compare treatment outcomes of epcoritamab from the EPCORE NHL-1 trial with individual patient data from clinical practice cohorts treated with chemoimmunotherapy (CIT) and novel therapies (polatuzumab-based regimens, tafasitamab-based regimens, and chimeric antigen receptor T-cell [CAR T] therapies) for third-line or later R/R large B-cell lymphoma (LBCL) and DLBCL. In this analysis, epcoritamab demonstrated significantly better response rates and overall survival rates than CIT, polatuzumab-based regimens, and tafasitamab-based regimens. No statistically significant differences in response rates or survival were found for epcoritamab compared with CAR T in R/R LBCL.

Original language	English
Article number	69
Journal	Journal of Hematology and Oncology
Volume	17
Issue number	1
DOIs	https://doi.org/10.1186/s13045-024-01594-x
State	Published - Dec 2024

ASJC Scopus subject areas

Hematology
Molecular Biology
Oncology
Cancer Research

Keywords

Diffuse large B-cell lymphoma
Electronic health records
Mortality
Non-Hodgkin lymphoma
Propensity score weighting
Proportional-hazards models
Retrospective studies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13045-024-01594-x

Fingerprint

Dive into the research topics of 'Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this

Rosenthal, A., Munoz, J., Jun, M., Wang, T., Mutebi, A., Wang, A., Yang, S., Osei-Bonsu, K., Elliott, B., Rivas Navarro, F., Yu, J., Brodkin, S., Sacchi, M., & Ip, A. (2024). Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma. Journal of Hematology and Oncology, 17(1), Article 69. https://doi.org/10.1186/s13045-024-01594-x

@article{18c428e25d33432ba72f457362759527,

title = "Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma",

abstract = "Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of therapy, albeit with scant evidence on the comparative effectiveness of these therapies. This study used inverse probability of treatment weighting to indirectly compare treatment outcomes of epcoritamab from the EPCORE NHL-1 trial with individual patient data from clinical practice cohorts treated with chemoimmunotherapy (CIT) and novel therapies (polatuzumab-based regimens, tafasitamab-based regimens, and chimeric antigen receptor T-cell [CAR T] therapies) for third-line or later R/R large B-cell lymphoma (LBCL) and DLBCL. In this analysis, epcoritamab demonstrated significantly better response rates and overall survival rates than CIT, polatuzumab-based regimens, and tafasitamab-based regimens. No statistically significant differences in response rates or survival were found for epcoritamab compared with CAR T in R/R LBCL.",

keywords = "Diffuse large B-cell lymphoma, Electronic health records, Mortality, Non-Hodgkin lymphoma, Propensity score weighting, Proportional-hazards models, Retrospective studies",

author = "Allison Rosenthal and Javier Munoz and Monika Jun and Tongsheng Wang and Alex Mutebi and Anthony Wang and Shibing Yang and Kojo Osei-Bonsu and Brian Elliott and {Rivas Navarro}, Fernando and Junhua Yu and Samantha Brodkin and Mariana Sacchi and Andrew Ip",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

doi = "10.1186/s13045-024-01594-x",

language = "English",

volume = "17",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central Ltd",

number = "1",

}

Rosenthal, A, Munoz, J, Jun, M, Wang, T, Mutebi, A, Wang, A, Yang, S, Osei-Bonsu, K, Elliott, B, Rivas Navarro, F, Yu, J, Brodkin, S, Sacchi, M & Ip, A 2024, 'Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma', Journal of Hematology and Oncology, vol. 17, no. 1, 69. https://doi.org/10.1186/s13045-024-01594-x

Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma. / Rosenthal, Allison; Munoz, Javier; Jun, Monika et al.
In: Journal of Hematology and Oncology, Vol. 17, No. 1, 69, 12.2024.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma

AU - Rosenthal, Allison

AU - Munoz, Javier

AU - Jun, Monika

AU - Wang, Tongsheng

AU - Mutebi, Alex

AU - Wang, Anthony

AU - Yang, Shibing

AU - Osei-Bonsu, Kojo

AU - Elliott, Brian

AU - Rivas Navarro, Fernando

AU - Yu, Junhua

AU - Brodkin, Samantha

AU - Sacchi, Mariana

AU - Ip, Andrew

PY - 2024/12

Y1 - 2024/12

N2 - Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of therapy, albeit with scant evidence on the comparative effectiveness of these therapies. This study used inverse probability of treatment weighting to indirectly compare treatment outcomes of epcoritamab from the EPCORE NHL-1 trial with individual patient data from clinical practice cohorts treated with chemoimmunotherapy (CIT) and novel therapies (polatuzumab-based regimens, tafasitamab-based regimens, and chimeric antigen receptor T-cell [CAR T] therapies) for third-line or later R/R large B-cell lymphoma (LBCL) and DLBCL. In this analysis, epcoritamab demonstrated significantly better response rates and overall survival rates than CIT, polatuzumab-based regimens, and tafasitamab-based regimens. No statistically significant differences in response rates or survival were found for epcoritamab compared with CAR T in R/R LBCL.

AB - Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of therapy, albeit with scant evidence on the comparative effectiveness of these therapies. This study used inverse probability of treatment weighting to indirectly compare treatment outcomes of epcoritamab from the EPCORE NHL-1 trial with individual patient data from clinical practice cohorts treated with chemoimmunotherapy (CIT) and novel therapies (polatuzumab-based regimens, tafasitamab-based regimens, and chimeric antigen receptor T-cell [CAR T] therapies) for third-line or later R/R large B-cell lymphoma (LBCL) and DLBCL. In this analysis, epcoritamab demonstrated significantly better response rates and overall survival rates than CIT, polatuzumab-based regimens, and tafasitamab-based regimens. No statistically significant differences in response rates or survival were found for epcoritamab compared with CAR T in R/R LBCL.

KW - Diffuse large B-cell lymphoma

KW - Electronic health records

KW - Mortality

KW - Non-Hodgkin lymphoma

KW - Propensity score weighting

KW - Proportional-hazards models

KW - Retrospective studies

UR - http://www.scopus.com/inward/record.url?scp=85201425019&partnerID=8YFLogxK

U2 - 10.1186/s13045-024-01594-x

DO - 10.1186/s13045-024-01594-x

M3 - Letter

C2 - 39152509

SN - 1756-8722

VL - 17

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 69

ER -

Rosenthal A, Munoz J, Jun M, Wang T, Mutebi A, Wang A et al. Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma. Journal of Hematology and Oncology. 2024 Dec;17(1):69. doi: 10.1186/s13045-024-01594-x

Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma

Abstract

ASJC Scopus subject areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this